These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28714417)

  • 1. Molecular Targeting of ERKs/RSK2 Signaling in Cancers.
    Cho YY
    Curr Pharm Des; 2017 Nov; 23(29):4247-4258. PubMed ID: 28714417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of magnolin on ERKs inhibits Ras/ERKs/RSK2-signaling-mediated neoplastic cell transformation.
    Lee CJ; Lee HS; Ryu HW; Lee MH; Lee JY; Li Y; Dong Z; Lee HK; Oh SR; Cho YY
    Carcinogenesis; 2014 Feb; 35(2):432-41. PubMed ID: 24031026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting RSK2 in human malignancies.
    Kang S; Chen J
    Expert Opin Ther Targets; 2011 Jan; 15(1):11-20. PubMed ID: 20969498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p90 ribosomal S6 kinase 2 exerts a tonic brake on G protein-coupled receptor signaling.
    Sheffler DJ; Kroeze WK; Garcia BG; Deutch AY; Hufeisen SJ; Leahy P; Brüning JC; Roth BL
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4717-22. PubMed ID: 16537434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway.
    Lee CJ; Lee MH; Yoo SM; Choi KI; Song JH; Jang JH; Oh SR; Ryu HW; Lee HS; Surh YJ; Cho YY
    BMC Cancer; 2015 Aug; 15():576. PubMed ID: 26253302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RSK2 and its binding partners in cell proliferation, transformation and cancer development.
    Cho YY
    Arch Pharm Res; 2017 Mar; 40(3):291-303. PubMed ID: 28013489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study.
    Casalvieri KA; Matheson CJ; Backos DS; Reigan P
    Bioorg Med Chem; 2020 Mar; 28(5):115303. PubMed ID: 31982240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.
    Zhong Y; Xue M; Zhao X; Yuan J; Liu X; Huang J; Zhao Z; Li H; Xu Y
    Bioorg Med Chem; 2013 Apr; 21(7):1724-34. PubMed ID: 23434140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of the Coffin-Lowry syndrome-associated gene RSK2 alters ERK activity, synaptic function and axonal transport in Drosophila motoneurons.
    Beck K; Ehmann N; Andlauer TF; Ljaschenko D; Strecker K; Fischer M; Kittel RJ; Raabe T
    Dis Model Mech; 2015 Nov; 8(11):1389-400. PubMed ID: 26398944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribosomal S6 kinase 2-forkhead box protein O4 signaling pathway plays an essential role in melanogenesis.
    Jeung D; Lee GE; Chen W; Byun J; Nam SB; Park YM; Lee HS; Kang HC; Lee JY; Kim KD; Hong YS; Lee CJ; Kim DJ; Cho YY
    Sci Rep; 2024 Apr; 14(1):9440. PubMed ID: 38658799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P90 Ribosomal s6 kinase 2 negatively regulates axon growth in motoneurons.
    Fischer M; Pereira PM; Holtmann B; Simon CM; Hanauer A; Heisenberg M; Sendtner M
    Mol Cell Neurosci; 2009 Oct; 42(2):134-41. PubMed ID: 19555761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P90 ribosomal S6 kinases: A bona fide target for novel targeted anticancer therapies?
    Koutsougianni F; Alexopoulou D; Uvez A; Lamprianidou A; Sereti E; Tsimplouli C; Ilkay Armutak E; Dimas K
    Biochem Pharmacol; 2023 Apr; 210():115488. PubMed ID: 36889445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of ERK/RSK2-driven NFκB gene expression and cancer cell proliferation by kurarinone, a lavandulyl flavanone isolated from Sophora flavescens ait. roots.
    Berghe WV; De Naeyer A; Dijsselbloem N; David JP; De Keukeleire D; Haegeman G
    Endocr Metab Immune Disord Drug Targets; 2011 Sep; 11(3):247-61. PubMed ID: 21831037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
    Kang S; Dong S; Gu TL; Guo A; Cohen MS; Lonial S; Khoury HJ; Fabbro D; Gilliland DG; Bergsagel PL; Taunton J; Polakiewicz RD; Chen J
    Cancer Cell; 2007 Sep; 12(3):201-14. PubMed ID: 17785202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasting roles of neuronal Msk1 and Rsk2 in Bad phosphorylation and feedback regulation of Erk signalling.
    Clark CJ; McDade DM; O'Shaughnessy CT; Morris BJ
    J Neurochem; 2007 Aug; 102(4):1024-34. PubMed ID: 17663748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.
    Shimura Y; Kuroda J; Ri M; Nagoshi H; Yamamoto-Sugitani M; Kobayashi T; Kiyota M; Nakayama R; Mizutani S; Chinen Y; Sakamoto N; Matsumoto Y; Horiike S; Shiotsu Y; Iida S; Taniwaki M
    Mol Cancer Ther; 2012 Dec; 11(12):2600-9. PubMed ID: 23012246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p90 ribosomal S6 kinase potentiates cisplatin activity in A549 human lung adenocarcinoma cells.
    Abdulrahman N; Siveen KS; Joseph JM; Osman A; Yalcin HC; Hasan A; Uddin S; Mraiche F
    J Pharm Pharmacol; 2020 Nov; 72(11):1536-1545. PubMed ID: 32667058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
    Qiu Q; Jiang J; Lin L; Cheng S; Xin D; Jiang W; Shen J; Hu Z
    Int J Oncol; 2016 Jun; 48(6):2508-20. PubMed ID: 27082640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of inhibitors against p90 ribosomal S6 kinase 2 (RSK2) through structure-based virtual screening with the inhibitor-constrained refined homology model.
    Li S; Zhou Y; Lu W; Zhong Y; Song W; Liu K; Huang J; Zhao Z; Xu Y; Liu X; Li H
    J Chem Inf Model; 2011 Nov; 51(11):2939-47. PubMed ID: 21995341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isobavachalcone exerts anti‑proliferative and pro‑apoptotic effects on human liver cancer cells by targeting the ERKs/RSK2 signaling pathway.
    Li B; Xu N; Wan Z; Ma L; Li H; Cai W; Chen X; Huang Z; He Z
    Oncol Rep; 2019 Jun; 41(6):3355-3366. PubMed ID: 30942462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.